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Abstract
Background: RIZ1 expression and activity are reduced in many cancers. In AML cell lines and
patient material, RIZ1 expression is reduced relative to normal bone marrow. In chronic
myelogenous leukemia (CML), blastic transformation is associated with loss of heterozygosity in
the region where RIZ1 is located. RIZ1 is a PR domain methyltransferase that methylates histone
H3 lysine 9, a modification important for transcriptional repression. In CML blast crisis cell lines
RIZ1 represses insulin-like growth factor-1 expression and autocrine signaling. Together these
observations suggest that RIZ1 may have a role in the chronic phase to blast crisis transition in
CML.
Results:  In CML patient material, we observed that RIZ1 expression was decreased during
progression from chronic phase to blast crisis. RIZ1 was expressed in mature myeloid and CD34+
cells demonstrating that decreased RIZ1 expression in blast crisis is not due to an increased
immature cell population. Expression of RIZ1 CML blast crisis cell lines decreased proliferation,
increased apoptosis, and enhanced differentiation.
Conclusion: RIZ1 is a candidate tumor suppressor gene whose expression is decreased in blast
crisis. Loss of RIZ1 activity results in decreased apoptosis and differentiation and enhanced
proliferation. Together these results suggest that loss of RIZ1 expression will lead to an increase
in myeloid blast cell population resulting in CML progression.
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Background
Molecular mechanisms responsible for driving the transi-
tion of chronic myelogenous leukemia (CML) from
chronic phase to blast crisis are not well characterized.
CML evolves from a chronic phase that is associated with
the Philadelphia chromosome to a blast crisis phase,
which is associated with additional chromosome or
molecular aberrations. Evolution to blast crisis is corre-
lated with frequent loss of heterozygosity at chromosome
region 1p36 [1]. RIZ1, a PR domain methyltransferase, is
located at 1p36. RIZ1 methylates histone H3 lysine 9, a
modification important for transcriptional repression [2].
RIZ1 expression and activity are reduced in many human
cancers by genetic and epigenetic mechanisms [3,4]. RIZ1
expression is reduced in acute myeloid leukemia [5] and
the RIZ1 knockout mouse has a high incidence of diffuse
large B-cell lymphoma [4]. RIZ1 also regulates IGF-1 sign-
aling in CML blast crisis cell lines [6]. Together these data
suggest that decreased RIZ1 expression may contribute to
CML progression. We investigated whether RIZ1 expres-
sion was reduced during CML progression and whether
RIZ1 induced phenotypes that support its role as a candi-
date tumor suppressor.
Results and discussion
We characterized RIZ1 expression in matched bone mar-
row biopsies from seven CML patients in chronic phase,
accelerated phase, or myeloid blast crisis by immunohis-
tochemistry (Fig 1a). Anti-RIZ1 antibody is specific for the
N-terminus of RIZ1 and thus does not recognize the RIZ2
isoform [6]. Previously this antibody has been used to
specifically detect RIZ1 in flow cytometry [6], Western
analysis [6], and chromatin immunoprecipitation assays
[2,6]. We observed strong cytoplasmic and nuclear RIZ1
expression during chronic phase in all cases, which was
similar to RIZ1 expression in normal bone marrow (Fig
1a, b). Five of six cases in blast crisis had markedly
reduced RIZ1 expression (Cases 1–5). In Case 1, the
patient had focal blast crisis and RIZ1 expression was
stronger in areas not involved in the blast foci. One blast
crisis patient (Case 7) and an accelerated phase patient
(Case 6) showed no appreciable change in RIZ1 expres-
sion. To validate these results further, we analyzed RIZ1
expression in a CML tissue microarray containing a larger
cohort of unmatched bone marrow biopsies in chronic
phase, accelerated phase, and blast crisis by immunohis-
tochemistry. We observed a significant decrease in RIZ1
expression (P = 0.015) in blast crisis compared to chronic
phase biopsies (Fig 1c). We did not observe any signifi-
cant differences in RIZ1 expression between chronic phase
and accelerated phase or between accelerated phase and
blast crisis. The mean value for RIZ1 expression in blast
crisis separates high and low RIZ1 expressing biopsies and
was approximately equal to the lower standard deviation
for RIZ1 expression in chronic phase. This is consistent
with other molecular defects in the high RIZ1 expression
biopsies contributing to the chronic phase to blast crisis
transition. Abnormalities of proto-oncogenes, such as
RAS and MYC, or of tumor suppressor genes, such as
mutations of the p53 gene, absence of RB protein, and
homozygous deletions of the p16INK4a gene, have been
reported to occur during the chronic phase to blast crisis
transition [7].
To confirm that low RIZ1 expression was correlated with
myeloid blast crisis and not due to low RIZ1 expression in
immature hematopoietic cells, we compared RIZ1 expres-
sion in immature and mature hematopoietic cells. We
observed RIZ1 expression in both immature and differen-
tiated cells in chronic phase and control bone marrow
(Fig 1a). RIZ1 expression was maintained in the immature
cells of two CML patients, one in accelerated phase with
15% blasts (Case 6) and the other in blast crisis (Case 7),
indicating that low RIZ1 expression was not an inherent
property of immature hematopoietic cells. We also meas-
ured RIZ1 expression in CD34+ cells, granulocytes, and
monocytes from G-CSF mobilized peripheral blood (Fig
2). RIZ1 was expressed in mature myeloid and CD34+
cells, indicating that differences in RIZ1 expression in
chronic phase and blast crisis were not a reflection of
increased immature cell population in blast crisis.
The mechanism for decreased RIZ1 expression in CML
blast crisis is not known. One possible explanation is that
the RIZ1 promoter CpG island is aberrantly hypermethyl-
ated. In the CML blast crisis cell line, K562, the RIZ1 pro-
moter is hypermethylated and addition of a methylation
inhibitor, 5-aza-2'-deoxycytidine, induces RIZ1 expres-
sion [8]. Epigenetic silencing has also been reported to
reduce RIZ1 expression in other cancers [3].
We used CML blast crisis cell lines, K562, YN-1, and ERY-
1, which express immature erythroid cell features, and
JURL-MK1, which can undergo megakaryocytic differenti-
ation, as model systems analyzing the effects of RIZ1
expression. We previously used these cells to transiently
express RIZ1 [6]. We monitored viability and apoptosis of
RIZ1-transfected cell lines using trypan blue exclusion and
annexin V assays, respectively. K562, YN-1, and ERY-1
were less viable when transfected with pRIZ1 than JURL-
MK1 (Fig 3a). Transient transfection of pRIZ1 increased
the number of cells undergoing early and late apoptosis in
all cell lines (Fig 3b). Similar results have been reported
for the forced expression of RIZ1 in breast cancer [9],
hepatoma [10], and promyelocytic leukemia [11] cell
lines, where RIZ1 expression causes cell cycle arrest and
cell death and a decrease in proliferation.
K562, YN-1, and ERY-1 express low levels of hemoglobin,
reflecting their myeloid/erythroid progenitor phenotype.Journal of Hematology & Oncology 2009, 2:28 http://www.jhoonline.org/content/2/1/28
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We used benzidine staining to monitor whether RIZ1
expression promotes erythroid differentiation. Transient
expression of RIZ1 in K562, YN-1, and ERY-1 was too
toxic to measure erythroid differentiation as the benzidine
assay requires incubation times longer than one day. Pre-
viously, we generated a stable RIZ1 expressing K562 cell
line (K562+RIZ1) that expresses less toxic levels of RIZ1
[6]. Stable expression of RIZ1 in K562 increases erythroid
differentiation compared to K562 alone (Fig 4a). To con-
firm that RIZ1 is responsible for enhanced erythroid dif-
ferentiation in K562+RIZ1 cell line, we measured
erythroid differentiation in K562+RIZ1 transfected with a
plasmid that expresses RIZ1 shRNA (pRIZ1shRNA).
Expression of pRIZ1shRNA in K562+RIZ1 reduced RIZ1
protein expression [6] and erythroid differentiation to lev-
els similar to K562 (Fig 4b). ERY-1 and YN-1 have higher
endogenous RIZ1 expression than K562 and therefore we
monitored the effect of pRIZ1shRNA on erythroid differ-
entiation directly in these cell lines. Expression of
pRIZ1shRNA in ERY-1 and YN-1 decreased RIZ1 expres-
sion and erythroid differentiation (Fig 4c, d).
We analyzed the effect of RIZ1 expression on megakaryo-
cytic differentiation in JURL-MK1 cells by measuring
changes in CD33 and CD117 using flow cytometry and
immunocytochemistry. CD33 and CD117 are present in
myeloid progenitors and their expression decreases with
maturation and differentiation. Transient transfection of
RIZ1 expression in bone marrow of CML patients Figure 1
RIZ1 expression in bone marrow of CML patients. (a) Immunohistochemical analysis of matched bone marrow trephine 
biopsies and bone marrow aspirate clot samples from patients in chronic phase and accelerated phase or myeloid blast crisis 
using an anti-RIZ1 antibody. (b) RIZ1 expression in normal bone marrow and normal bone marrow staining in the absence of 
RIZ1 primary antibody (Negative control). (c) Immunohistochemical analysis of RIZ1 expression in unmatched patient bone 
marrow biopsies and clot sections from chronic phase (CP) (N = 10), accelerated phase (AP) (N = 7) and blast crisis (BC) (N 
= 15) using an anti-RIZ1 monoclonal antibody. Relative RIZ1 expression represents 3,3-diaminobenzidine chromagen intensity. 
Mean RIZ1 expression for each group is shown as a black line and errors bars represent the standard deviation.
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pRIZ1 into JURL-MK1 decreased CD33 and CD117
expression as monitored by flow cytometry (Fig 4e).
Immunohistochemical staining using CD117 antibody
also shows that transient transfection of pRIZ1 into JURL-
MK1 decreased CD117 expression (Fig 4e).
Conclusion
These results build upon previous observations that a
putative CML tumor suppressor gene is present at 1p36
that exhibits loss of heterozygosity during transformation
from chronic phase to blast crisis [1]. We propose a model
whereby in chronic phase CML there is an expansion of
BCR/ABL positive CML progenitor cells that maintain the
ability to undergo apoptosis and differentiation. Epige-
netic or genetic aberrations in RIZ1 expression and activ-
ity result in a blockage of apoptotic and differentiation
pathways, which causes expansion of the myeloid blast
cell population.
Methods
Cell Lines, CD34+ Cells, and CML Patient Material
K562 is from ATCC (Manassas, VA, USA), JURL-MK1 is
from DSMZ (Braunschweig, Germany), YN-1, ERY-1, and
K562+RIZ1 have been described previously [6]. CD34+
cells were purified from G-CSF mobilized peripheral
blood using an AutoMACs Separator with a Direct CD34
Progenitor Cell Isolation Kit from Miltenyi Biotech
(Auburn, CA, USA). Fixed bone marrow specimens from
CML chronic phase patients that progressed to accelerated
phase or blast crisis were obtained from the Department
of Pathology and Laboratory Medicine (Indiana Univer-
sity). Patients were diagnosed in chronic phase between
1997–2000 and in accelerated phase or blast crisis
between 2000–2004. Unmatched patient CML bone mar-
row biopsies and clot sections were obtained from the MD
Anderson Cancer Center as described previously [12].
Patient samples were obtained with informed consent
according to institutional review board guidelines.
Cell Line Transfections and Assays
Plasmids were transfected into cell lines using the Nucle-
ofector system (Amaxa, Gaithersburg, MD, USA). Trans-
fection efficiencies for CML cell lines were: K562 – 74.5%
RIZ1 expression in G-CSF mobilized peripheral blood Figure 2
RIZ1 expression in G-CSF mobilized peripheral 
blood. Flow cytometry analysis of RIZ1 protein expression 
in granulocytes, monocytes, and CD34+ cells. (Con) repre-
sents flow cytometry analysis in the absence of the RIZ1 pri-
mary antibody.
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Effect of RIZ1 expression on cell viability and apoptosis in CML myeloid blast crisis model cell lines Figure 3
Effect of RIZ1 expression on cell viability and apoptosis in CML myeloid blast crisis model cell lines. (a) Viability 
assay for cell lines transfected with pRIZ1 (dashed line) or pcDNA3 control plasmid (solid line). (b) Annexin V assay of ERY-1, 
YN-1, JURL-MK1, and K562 one day after transfection with pRIZ1 (+) or pcDNA3 control plasmid (-). Percentages of apop-
totic cells were detected using annexin V-FITC and PI staining. Total percentage of cells undergoing early and end stage apop-
tosis are indicated. White histogram represents cells in early apoptosis (FITC+, PI-). Black histogram represents cells that are in 
the end stage of apoptosis or that are already dead (FITC+, PI+). Error bars represent standard deviation from three independ-
ent experiments.
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Effect of RIZ1 expression on differentiation in CML myeloid blast crisis model cell lines Figure 4
Effect of RIZ1 expression on differentiation in CML myeloid blast crisis model cell lines. (a) Benzidine staining 
assays comparing erythroid differentiation in K562 cells transfected with shRNA non-silencing control plasmid (K562), 
K562+RIZ1 cells transfected with shRNA non-silencing control plasmid (K562+RIZ1), and K562+RIZ1 cells transfected with 
pRIZ1shRNA (K562+RIZ1+shRNA). (b) Western analysis of RIZ1 expression in K562 transfected with shRNA non-silencing 
control plasmid (K562), K562+RIZ1 cells transfected with shRNA non-silencing control plasmid (K562+RIZ1), and K562+RIZ1 
cells transfected with pRIZ1shRNA (K562+RIZ1+shRNA). (c) RT-PCR analysis of RIZ1 mRNA expression in ERY-1 and YN-1 
transfected with shRNA non-silencing control plasmid (Con shRNA) or with pRIZ1shRNA (RIZ1 shRNA). Total RNA was 
reverse transcribed and cDNA amplified with RIZ1 and β-actin-specific primers. M represent DNA ladder and H2O represents 
RT-PCR reaction without template DNA. (d) Erythroid differentiation assay comparing ERY-1 and YN-1 after transfection with 
pRIZ1shRNA or shRNA non-silencing control plasmid (Con). Cell lines were transfected with pRIZ1shRNA or shRNA non-
silencing control plasmid and cultured for three days. Histograms show the percentage of benzidine-positive cells that were 
scored by light microscopy. Error bars represent the standard deviation from three independent experiments. (e) CD33 and 
CD117 expression in JURL-MK1 cells as compared with JURL-MK1 cells expressing RIZ1 (JURL-MK1+pRIZ). JURL-MK1 was 
transfected with pRIZ1 or pcDNA3 control plasmid (con) and cultured for three days. Panel (i) shows the fluorescence inten-
sity of phycoerythrin (PE)-conjugated antibody against CD33. Panel (ii) shows the fluorescence intensity of (PE)-conjugated 
antibody against CD117. Panels (iii) and (iv) show immunocytochemical staining using an anti-CD117 antibody in JURL-MK and 
JURL-MK1+pRIZ1 cells, respectively.
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ERY-1 – 68.6%, YN-1 – 75.3, JURL-MK1 – 77%. pRIZ1
(p3RIZRH4.1) was from Steele-Perkins et al, [4] and
pCDNA3 was from Invitrogen (Carlsbad, CA, USA).
pRIZ1shRNA and shRNA non-silencing control vector
were from OPEN Biosystems (Huntsville, AL, USA). Cell
viability, apoptosis, and hemoglobin staining were
assayed using Trypan blue dye exclusion, Annexin V-FITC
Apoptosis Detection Kit (BD Biosciences, San Jose, CA,
USA), and benzidine staining, respectively.
Flow Cytometry
Conjugated antibodies used for surface analysis of CD45,
CD34, CD33, and CD117 expression are from Beckman
Coulter (Fullerton, CA, USA). Intracellular RIZ1 expres-
sion was detected indirectly using anti-RIZ1 monoclonal
antibody (1:25 dilution; Abgent, San Diego, CA, USA)
and a FITC-conjugated secondary antibody following fix-
ation and permeabilization with IntraPrep reagent (Beck-
man Coulter).
Immunostaining
Immunohistochemical analysis of B5 fixed/paraffin
embedded and decalcified bone marrow trephine biop-
sies and B5 fixed/paraffin embedded bone marrow aspi-
rate clot samples was performed using an anti-RIZ1
monoclonal antibody (Abgent, San Diego, CA, USA)
(1:25 dilution) and a horseradish peroxidase-coupled sec-
ondary antibody. RIZ1 expression in unmatched patient
bone marrow biopsies and clot sections was calculated by
measuring intensity levels of 3,3-diaminobenzidine chro-
mogen staining (brown pixel intensity) that was normal-
ized to the area scanned using an ACIS® III scanner (Dako,
Carpinteria, CA, USA). Statistical differences between
chronic phase, accelerated phase, and blast crisis were
determined using an unpaired t-test.
RT-PCR
Total RNA was isolated from cell lines using the TRI-zol
reagent (Life Technologies). cDNA was synthesized from
total RNA using iScript cDNA synthesis kit (Bio-Rad Lab-
oratories, Hercules, CA). cDNA was amplified in a 50 μl
reaction containing Hotstar Taq DNA polymerase and
buffer (Qiagen), 100 pmol primers (RIZ1: 5'-AACATGT-
GCTGCGAGGACTT-3' and 5'-TTCTTCCCTTTCCGGCTCT
T-3'; β-Actin: 5' CCAAGGCCAACCGCGAGAAGAT-3' and
5'-TTGCTCGAAGTC CAGGGCGA-3'), and 0.25 μg cDNA.
Statistical Analysis
All the data are reported as mean± s.d. The differences
between the mean values were tested for statistical signif-
icance by the two-tailed Student's t-test (P-values).
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